Oxinas Partners Wealth Management’s Novavax NVAX Stock Holding History

Oxinas Partners Wealth Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,510	Closed	-$216K	–	141
2021 Q4	$216K	Buy	1,510 +10	+0.7%	+$1.72K	0.12%	133
2021 Q3	$311K	Hold	1,500	–	–	0.18%	114
2021 Q2	$318K	Hold	1,500	–	–	0.18%	114
2021 Q1	$272K	Buy	+1,500	New	+$299K	0.17%	112

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Oxinas Partners Wealth Management's NVAX Position: Q1 2022 in Review

Oxinas Partners Wealth Management sold out of Novavax (NVAX) in Q1 2022, closing a stake of 1,510 shares — an estimated $216K sold.

Oxinas Partners Wealth Management first reported a position in NVAX in Q1 2021 and held it in 4 quarters. The position peaked at $318K in Q2 2021. 381 funds tracked by Wall St. Rank hold NVAX as of Q1 2022.

Oxinas Partners Wealth Management reported no remaining Novavax position as of Q1 2022 after selling out during the quarter.
Oxinas Partners Wealth Management sold 1,510 Novavax shares in Q1 2022, an estimated $216K.
Oxinas Partners Wealth Management first reported a position in Novavax in Q1 2021 and held it in 4 quarters.
Oxinas Partners Wealth Management's Novavax position peaked at $318K in Q2 2021.
381 funds tracked by Wall St. Rank held Novavax as of Q1 2022.

Based on Oxinas Partners Wealth Management's 13F filing for Q1 2022, filed 20 Apr 2022.